Feasibility and safety of early initiation of a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor in patients with acute myocardial infarction undergoing primary PCI
Event:
ESC Congress 2020
Topic:
Lipid-Lowering Agents
Session:
Pharmacology and Pharmacotherapy ePosters
